Genetic medicines have the potential to transform the treatment of human disease across a wide range of therapeutic applications. Yet, the broad application of genetic medicines remains limited by today’s available delivery technologies. Aera was founded with a vision to unlock the potential of genetic medicines across a broad range of modalities and therapeutic areas.
Aera’s protein nanoparticle (PNP) delivery platform leverages the discovery of endogenous, human proteins that can self-assemble to form capsid-like structures and that can package and transfer nucleic acid cargo. This platform has the potential to address many of the limitations of today’s delivery technologies and to enable various genetic medicine modalities.
Aera is led by a distinguished team of scientists and company builders.
